share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  09/12 16:19

Moomoo AI 已提取核心訊息

On September 10, 2024, 180 Life Sciences Corp. announced the resignation of its Chief Financial Officer (CFO) and Secretary, Mr. Ozan Pamir, effective September 30, 2024. The resignation was not due to any disagreements with the company's operations, policies, or practices. Following this, on September 11, 2024, the Board appointed Mr. Omar Jimenez, a current board member, as the new CFO and Secretary, with his tenure beginning on September 30, 2024. Mr. Jimenez's qualifications and experience are detailed in the company's Annual Report filed on April 29, 2024. In conjunction with his new role, Mr. Jimenez will resign from his positions on the Company’s Compensation Committee, Nominating and Corporate Governance Committee, and as Chairman of the Audit Committee. The company plans to add new independent board members to fill these committees in the coming weeks. A press release on September 12, 2024, officially disclosed Mr. Jimenez's appointment. 180 Life Sciences Corp. is a clinical-stage biotechnology company focusing on developing treatments for chronic pain, inflammation, and fibrosis.
On September 10, 2024, 180 Life Sciences Corp. announced the resignation of its Chief Financial Officer (CFO) and Secretary, Mr. Ozan Pamir, effective September 30, 2024. The resignation was not due to any disagreements with the company's operations, policies, or practices. Following this, on September 11, 2024, the Board appointed Mr. Omar Jimenez, a current board member, as the new CFO and Secretary, with his tenure beginning on September 30, 2024. Mr. Jimenez's qualifications and experience are detailed in the company's Annual Report filed on April 29, 2024. In conjunction with his new role, Mr. Jimenez will resign from his positions on the Company’s Compensation Committee, Nominating and Corporate Governance Committee, and as Chairman of the Audit Committee. The company plans to add new independent board members to fill these committees in the coming weeks. A press release on September 12, 2024, officially disclosed Mr. Jimenez's appointment. 180 Life Sciences Corp. is a clinical-stage biotechnology company focusing on developing treatments for chronic pain, inflammation, and fibrosis.
2024年9月10日,180 Life Sciences Corp.宣佈其首席財務(致富金融(臨時代碼))官和秘書奧贊·帕米爾(Ozan Pamir)先生於2024年9月30日生效辭職。辭職並非因與公司運營、政策或實踐存在任何分歧。隨後,於2024年9月11日,董事會任命了現任董事會成員奧馬爾·希門內斯(Omar Jimenez)先生爲新的首席財務(致富金融(臨時代碼))官和秘書,任期自2024年9月30日開始。公司年度報告於2024年4月29日提交,詳細介紹了希門內斯先生的資格和經驗。伴隨新角色,希門內斯先生將辭去公司的薪酬委員會、提名和公司治理委員會以及審計委員會主席的職務。公司計劃在接下來的幾周內增加新的獨立董事會成員以填補這些委員會的空缺。2024年9月12日發佈的新聞稿正式披露了希門內斯先生的任命。180 Life Sciences Corp.是一家專注於開發治療慢性疼痛、炎症和纖維化的臨床階段生物技術公司。
2024年9月10日,180 Life Sciences Corp.宣佈其首席財務(致富金融(臨時代碼))官和秘書奧贊·帕米爾(Ozan Pamir)先生於2024年9月30日生效辭職。辭職並非因與公司運營、政策或實踐存在任何分歧。隨後,於2024年9月11日,董事會任命了現任董事會成員奧馬爾·希門內斯(Omar Jimenez)先生爲新的首席財務(致富金融(臨時代碼))官和秘書,任期自2024年9月30日開始。公司年度報告於2024年4月29日提交,詳細介紹了希門內斯先生的資格和經驗。伴隨新角色,希門內斯先生將辭去公司的薪酬委員會、提名和公司治理委員會以及審計委員會主席的職務。公司計劃在接下來的幾周內增加新的獨立董事會成員以填補這些委員會的空缺。2024年9月12日發佈的新聞稿正式披露了希門內斯先生的任命。180 Life Sciences Corp.是一家專注於開發治療慢性疼痛、炎症和纖維化的臨床階段生物技術公司。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息